CHAPTER 12 Approach to Various Skin Lesions
This chapter provides guidelines for the diagnosis and treatment of common skin lesions. Table 12-1 can be used as a guide for proper biopsy and treatment techniques. The specifics of performing the procedures are reviewed elsewhere in this textbook. These guidelines are not intended to be all-inclusive, but they do provide a framework for the approach to common skin lesions.
Angioma (Hemangioma)
If the angiomas are small, use a ball electrode to cauterize them lightly. If larger than 2 mm, local anesthesia may be needed. Tissue should be wiped away and the process repeated until no vessel is seen (Fig. 12-1). Focal cryotherapy or sclerotherapy will also work. If the angiomas are large, a superficial shave excision or curettement followed by light cautery of the base works best.
Acrochordon (Skin Tag)
Although many physicians prefer to use electrosurgery or cryotherapy to remove acrochordons, the most direct and simple approach is to elevate the tag with pickups and excise it with sharp tissue scissors at the level of the surrounding skin (Fig. 12-2). If it has a broad base, a local anesthetic may be required. Monsel’s solution (ferric subsulfate) or aluminum chloride may be used for hemostasis. It is essential to have good-quality scissors so the lesion is cut, not “pinched.”
Cryocautery can be effective, but it is difficult to limit the freeze solely to the tag. A unique method with liquid nitrogen is to use the Styrofoam cup method, dipping the flat pickups in the liquid, and then grasping the tag with the cooled metal. The tag usually necroses off. The tag should be frozen twice in the same visit. Special thickened metal forceps are available from Brymill Cryogenic Systems (Ellington, Conn) that stay colder longer and can be used to treat multiple lesions without having to dip into the liquid nitrogen repeatedly (Fig. 12-3).
Actinic Keratoses
Actinic keratoses (Fig. 12-4) are sun-induced, premalignant lesions. Single lesions can be shaved, cauterized, or, most commonly, treated with cryotherapy. When multiple lesions are present, they can be treated with 5-fluorouracil (5-FU, Efudex), masoprocol (Actinex) cream, imiquimod (Aldara) cream, or photodynamic therapy with δ-aminolevulinic acid (Levulan) in conjunction with light therapy (e.g., blue light, intense pulsed light [IPL]). Lesions that do not resolve require surgical sampling for histology. They are then frequently squamous cell carcinomas (SCCs; see treatment methods, later). The risk that actinic keratoses will progress to SCC is probably less than 1% in early lesions, and as high as 10% to 20% for persistent hypertrophic lesions. The patient should be counseled that both 5-FU and masoprocol cause significant erythema and tenderness in the areas treated. For 5-FU and masoprocol, the medication is applied twice a day for 3 to 4 weeks to the face and three to four times per day on the arms. (See patient education form online at www.expertconsult.com. The manufacturer will also provide a patient education videotape.) Treatment with imiquimod is significantly more expensive, with less efficacy (Table 12-2). Steroid creams may be used to reduce the inflammatory response. Alternatively, daily application of retinoic acid (Retin-A) 0.025% or 0.05% may resolve early lesions and prevent new ones. Protection from the sun is essential.
Agent and Preparation | Treatment Regimen | Cost of One Treatment |
---|---|---|
δ-Aminolevulinic acid (Levulan), 20% sol | + Blue light or intense pulsed light | $108.02+ |
Diclofenac (Solaraze), 3% gel | Twice daily for 60–90 days | $105.00 |
5-Fluorouracil (generic), 2% solution | Twice daily for 2–4 wk | $51.40 |
5-Fluorouracil (generic), 5% solution | Same | $74.50 |
5-Fluorouracil (Efudex) | ||
5% cream | Same | $102.25 |
2% solution | Same | $69.70 |
5% solution | Same | $102.90 |
5-Fluorouracil (Fluoroplex), 1% cream | Twice daily for 2–6 wk | $80.40 |
5-Fluorouracil (Carac), 0.5% cream | Once daily (max. 4 wk) | $98.10 |
Imiquimod (Aldara), 5% cream | Twice weekly for 16 wk | $518.76 |
Prices have increased significantly since 2004. The cost to the patient for one tube of Efudex 5% cream (40 g) on March 17, 2009 was $342.00, while the generic was $257.00 (Rite-Aid, Midland, Mich.)
From Imiquimod (Aldara) for actinic keratoses. Med Lett Drugs Ther 46:42–44, 2004.
Basal Cell Carcinoma
Basal cell carcinomas (BCCs) characteristically have small, centrally ulcerated depressions and raised, pearly borders (nodular-cystic type; (Fig. 12-5A and B). However, their actual appearance can vary markedly from the classic description. Sclerosing (or morpheaform; Fig. 12-5C) BCCs may manifest as flat lesions with nondescript borders. Others are nonhealing ulcerations that never do become elevated. Some are pigmented (Fig. 12-5D) and may be confused with seborrheic keratoses (SKs), nevi, or even melanomas. They may appear erythematous and bleed easily, mimicking a pyogenic granuloma. Superficial (Fig. 12-5E) BCCs commonly occur on the back and are flat and scaly. They may look like an SCC, actinic keratoses, eczema, or even tinea. A biopsy should be taken of all nonhealing, changing, or enlarging skin lesions. Once a diagnosis is made, proper treatment can be planned. Chronic sun exposure, chronic irritation, and the human papillomavirus appear to be the most common causative factors.
Figure 12-5 Basal cell carcinoma. A, Nodular; B, nodular ulcerative; C, morpheaform; D, pigmented; E, superficial.
BCCs usually involve the upper portions of the skin and, again, very rarely metastasize. Deaths are extremely rare and reportable. For the majority of lesions that are smaller than 1 cm, treatment with cautery and curettement (electrodesiccation and curettage [ED&C]) is a rapid and effective solution. Cure rates approach 95% to 98%, and scarring is usually minimal (Figs. 12-6 and 12-7). The technique is as follows:
Lesions in younger patients, larger-sized (>1 cm) lesions, lesions in more aggressive locations (nasolabial folds, preauricular areas, eyelids), sclerosing-type BCC lesions, recurrent lesions, and lesions with ill-defined margins may require complete excision to enable the pathologist to examine the margins. Remove 3 to 4 mm of normal skin around all edges (Table 12-3). Margins can be marked to aid in the histologic evaluation. Some physicians believe that excision is more cosmetically acceptable than cautery and curettement. An advantage of ED&C over cryotherapy is that the necrotic lesion can be “felt” with the curette, so the surgeon knows how far and deep to proceed with the scraping. If properly cared for, most lesions treated with ED&C will only have some mild depigmentation after 4 to 6 months. Although cryotherapy reportedly is very successful, the surgeon cannot often “feel” or see the margins of the tumor. All the various clinical factors should be weighed when selecting the method for lesion removal.
Lesion | Margins |
---|---|
Atypical nevi | |
Atypical or mild dysplasia | Be certain margins are clear (shave acceptable) |
Moderate dysplasia | 2–3 mm |
Severe dysplasia | 3 mm |
Actinic keratoses | 2–3 mm |
Bowen’s disease (squamous cell carcinoma in situ) | 3 mm |
Basal cell carcinoma | |
Superficial | 3 mm |
Nodular/ulcerative | 3 mm |
Morpheaform (sclerotic, “aggressive”) | 5 mm |
Squamous cell carcinoma | 5 mm |
Lentigo maligna (Hutchinson’s freckle) | 3 mm |
Lentigo maligna melanoma | As for melanoma, below |
Melanoma | |
In situ | 5 mm |
Invasive to 1 mm (no ulceration, low mitotic count) | 1 cm |
>1 mm depth of invasion or ulcerated, increased mitotic count | Refer |
Laser therapy can be used to ablate the lesions. Topical 5-FU and imiquimod have been approved to treat superficial BCCs. Cryotherapy has excellent results for lesions less than 1 cm wide. A good freeze 5 mm past the lesion is required, followed by thawing, then a repeat freeze (see Chapter 14, Cryosurgery). It is critical to note the thaw time. Cure rates of 98% are reported (see caveat previously).
Follow-up 3 months after treatment to ensure success of treatment is recommended. The patient must be followed closely because 30% of patients will develop new BCCs somewhere within 3 years (Table 12-4).
Cancer | Follow-up |
---|---|
Basal cell carcinoma | 3 mo |
Squamous cell carcinoma | 3 mo, 6 mo–1 yr |
Melanoma |
Squamous Cell Carcinoma
Squamous cell carcinoma (Fig. 12-8) often appears as a diffuse, nonhealing, crusted lesion. It frequently occurs at the base of an actinic keratosis or cutaneous lesion. The lesions may be multifocal in origin and, as with actinic lesions, are due to solar damage. SCCs are more aggressive than BCCs and can metastasize. Because the margins of these lesions are often not very clear, many clinicians prefer to excise all invasive SCCs. If 5-FU (Efudex) or masoprocol (Actinex) creams or cryotherapy are used to treat diffuse actinic changes, any post-treatment residual lesions (after 6 to 8 weeks) should be removed for biopsy to rule out SCC. When a biopsy is performed on a suspected SCC, try to include portions of the central area. A deep punch biopsy into subcutaneous fat is preferred by many pathologists, but a deep saucer-type shave is adequate, with definitive therapy after pathology results. Early or small lesions can be treated with cautery and curettement (see Figs. 12-6 and 12-7) or with cryotherapy, with excellent results (see earlier). If the lesion is excised, remove at least 5 mm of normal tissue to be sure all margins are clear (see Table 12-3).
Lesions (especially the more invasive ones) should be reevaluated in 3 and 6 months to document cure. Evaluation of the lymph nodes draining the area is also prudent (see Table 12-4).
Condylomata Acuminata
Many therapeutic interventions are available to treat condylomata acuminata. See Chapter 155, Treatment of Noncervical Condylomata Acuminata.
Dermatofibroma
Dermatofibromas (Fig. 12-9) often occur on the anterior surface of the lower leg. The etiology is unknown, but dermatofibromas may represent a fibrous reaction to trauma, viral infection, or insect bites. They are often confused with verrucae or nevi. Dermatofibromas do not progress to cancers, and once the diagnosis of dermatofibroma is confirmed, the physician often can merely observe the lesion. However, until the lesion is sampled, only an educated guess is possible. Many BCCs of the lower extremities mimic dermatofibromas. A rapidly growing lesion could be a dermatofibrosarcoma. Dermatofibromas are generally deep-seated and require excision if complete removal is desired. Cryotherapy can be attempted but dermatofibromas are generally quite cryoresistant. Because the lesions are often on the legs and are cut while shaving, the most judicious approach is to shave the lesion flat, which provides tissue for confirmatory diagnosis and reduces the likelihood of further trauma. A pigmented spot may remain, but at least it will be flat. If final results are not satisfactory, it can still be excised or cryotherapy can then be attempted.
Cutaneous Horn
A cutaneous horn (Fig. 12-10) is a type of actinic keratosis. Use caution to rule out an early SCC at the base. Usually a deep saucer-type shave is performed, followed by cautery. Tissue should be sent to pathology for verification.
Keratoacanthoma
Keratoacanthoma (Fig. 12-11) is a common, “benign” epithelial tumor found in elderly patients. This lesion may have a viral etiology. Keratoacanthoma often is confused with SCC, but it is a distinct entity and often considered an “SCC variant” because it cannot be differentiated histologically from SCC. The history of rapid growth is critical for the pathologist to make the proper diagnosis.